company background image
500257 logo

Lupin BSE:500257 Stock Report

Last Price

₹1.80k

Market Cap

₹828.4b

7D

1.6%

1Y

93.1%

Updated

12 Jul, 2024

Data

Company Financials +

500257 Stock Overview

Operates as a pharmaceutical company in India and internationally.

500257 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance5/6
Financial Health6/6
Dividends4/6

Lupin Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lupin
Historical stock prices
Current Share Price₹1,797.10
52 Week High₹1,837.00
52 Week Low₹925.85
Beta0.61
11 Month Change11.94%
3 Month Change10.71%
1 Year Change93.10%
33 Year Change52.30%
5 Year Change140.54%
Change since IPO60,306.72%

Recent News & Updates

Recent updates

Shareholder Returns

500257IN PharmaceuticalsIN Market
7D1.6%1.7%0.8%
1Y93.1%51.8%46.0%

Return vs Industry: 500257 exceeded the Indian Pharmaceuticals industry which returned 51.8% over the past year.

Return vs Market: 500257 exceeded the Indian Market which returned 46% over the past year.

Price Volatility

Is 500257's price volatile compared to industry and market?
500257 volatility
500257 Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement6.4%
10% most volatile stocks in IN Market9.6%
10% least volatile stocks in IN Market4.2%

Stable Share Price: 500257 has not had significant price volatility in the past 3 months.

Volatility Over Time: 500257's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196820,933Vinita Guptawww.lupin.com

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities.

Lupin Limited Fundamentals Summary

How do Lupin's earnings and revenue compare to its market cap?
500257 fundamental statistics
Market cap₹828.43b
Earnings (TTM)₹19.14b
Revenue (TTM)₹200.11b

42.8x

P/E Ratio

4.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
500257 income statement (TTM)
Revenue₹200.11b
Cost of Revenue₹71.12b
Gross Profit₹128.99b
Other Expenses₹109.85b
Earnings₹19.14b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)41.99
Gross Margin64.46%
Net Profit Margin9.57%
Debt/Equity Ratio18.6%

How did 500257 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

19%

Payout Ratio

Does 500257 pay a reliable dividends?

See 500257 dividend history and benchmarks
When do you need to buy 500257 by to receive an upcoming dividend?
Lupin dividend dates
Ex Dividend DateJul 16 2024
Dividend Pay DateSep 01 2024
Days until Ex dividend3 days
Days until Dividend pay date50 days

Does 500257 pay a reliable dividends?

See 500257 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.